Biora Therapeutics (Biora Therapeutics) Net Issuance of Preferred Stock : $0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Biora Therapeutics Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Biora Therapeutics's net issuance of preferred for the three months ended in Dec. 2023 was $0.00 Mil. The number is 0, which means that Biora Therapeutics has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Biora Therapeutics's net issuance of preferred for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.

Biora Therapeutics Net Issuance of Preferred Stock Historical Data

The historical data trend for Biora Therapeutics's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biora Therapeutics Net Issuance of Preferred Stock Chart

Biora Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Issuance of Preferred Stock

Get a 7-Day Free Trial

79.04

21.31

Biora Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Issuance of Preferred Stock	Get a 7-Day Free Trial															-	-	-	-	-

Biora Therapeutics Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Biora Therapeutics Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Biora Therapeutics's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Biora Therapeutics (Biora Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biora Therapeutics Inc (NAS:BIOR) » Definitions » Net Issuance of Preferred Stock

Comparable Companies

Traded in Other Exchanges

4ZU0:Germany 4ZU0:Germany

Address

4330 La Jolla Village Drive, Suite 300, San Diego, CA, USA, 92122

Website

https://www.bioratherapeutics.com

Biora Therapeutics Inc is a biotechnology company engaged in developing oral biotherapeutics. Its drug-device combinations could enable new treatment approaches in the delivery of therapeutics in two main areas: Targeted delivery of therapeutics to the site of disease in the gastrointestinal ("GI") tract, which is designed to improve outcomes for patients with Inflammatory Bowel Disease (IBD); and Systemic delivery of biotherapeutics, which are designed to replace injection with needle-free, oral delivery technology. Geographically, it operates only in the United States.

Executives

Athyrium Opportunities Iii Co-invest 1 Lp	10 percent owner	505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Surbhi Sarna	director	ONE PENUMBRA PLACE, ALAMEDA CA 94502
Aditya P. Mohanty	director, officer: Chief Executive Officer	1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Jill Ann Howe	director	C/O DTX PHARMA, INC., 10655 SORRENTO VALLEY ROAD, SUITE 100, SAN DIEGO CA 92121
Athyrium Capital Management, Lp	10 percent owner	505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Athyrium Opportunities Fund (a) Lp	10 percent owner	605 THIRD AVENUE, 22ND FLOOR, NEW YORK NY 10158
Hutan Hashemi	officer: Chief Compliance Officer	4330 LA JOLLA VILLAGE DRIVE, SUITE 200, SAN DIEGO CA 92122
Damon Silvestry	officer: Chief Operating Officer	4330 LA JOLLA VILLAGE DRIVE, SUITE 200, SAN DIEGO CA 92122
Jeffrey D. Alter	director	4330 LA JOLLA VILLAGE DRIVE, SUITE 200, SAN DIEGO CA 92122
Athyrium Opportunities Iii Acquisition Lp	10 percent owner	505 FIFTH AVENUE, 18TH FLOOR, NEW YORK NY 10017
Harry Stylli	director, officer: Chairman & CEO	3595 JOHN HOPKINS CT, SAN DIEGO CA 92121
Matthew T Cooper	officer: Chief Scientific Officer	4330 LA JOLLA VILLAGE DRIVE, SUITE 200, SAN DIEGO CA 92122
Athyrium Opportunities Advisers Llc	10 percent owner	1209 AVENUE OF THE AMERICAS, NEW YORK NY 10104
Athyrium Opportunities Associates Gp Llc	10 percent owner	1209 AVENUE OF THE AMERICAS, NEW YORK NY 10104
Athyrium Opportunities Associates Lp	10 percent owner	1209 AVENUE OF THE AMERICAS, NEW YORK NY 10104